The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 18, 2022
Filed:
Nov. 16, 2016
Ampsource Biopharma Shanghai Inc., Shanghai, CN;
Furen Pharmaceutical Group Co., Ltd, Luyi Zhoukou, CN;
Pharmab, Inc., Shanghai, CN;
Kaifeng Pharmaceutical (Group) Co., Ltd., Kaifeng, CN;
Qiang Li, Shanghai, CN;
Wenchen Zhu, Luyi Zhoukou, CN;
Yuanli Li, Shanghai, CN;
Chenggong Zhu, Luyi Zhoukou, CN;
Yongjuan Gao, Shanghai, CN;
Zijia Ren, Kaifeng, CN;
Luyan Zhu, Kaifeng, CN;
Naichao Sun, Shanghai, CN;
Xiaoshan Wang, Kaifeng, CN;
Bin Liu, Kaifeng, CN;
Zhi Li, Kaifeng, CN;
Wenwen Wang, Kaifeng, CN;
Ming Jiang, Kaifeng, CN;
Qilei Wang, Kaifeng, CN;
Lirui Wang, Kaifeng, CN;
Shuya Wang, Kaifeng, CN;
Songlin Zhu, Kaifeng, CN;
Jie Gao, Kaifeng, CN;
Hongsheng Su, Kaifeng, CN;
Ampsource Biopharma Shanghai Inc., Shanghai, CN;
Furen Pharmaceutical Group Co., Ltd, Luyi Zhoukou, CN;
Pharmab, Inc., Shanghai, CN;
Kaifeng Pharmaceutical (Group) Co., Ltd., Kaifeng, CN;
Abstract
A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin β-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.